Metabolon, Inc., has appointed Dr. Michael Milburn as its chief scientific officer. Previously he was with Sirtris Pharmaceuticals.

Milburn is a 15 years veteran of biotech and pharmaceutical companies. At Sirtris, he led the preclinical/clinical development of projects in the areas of metabolic disease and neurodegeneration. He has held senior positions at Plexxikon, where he was responsible for the development of the company’s proprietary high-throughput co-crystallography drug discovery platform; Structural Genomix and GlaxoSmithKline.

“Mike’s extensive background and proven leadership ability in drug discovery and development will be valuable as we continue our biomarker discovery projects and expand our business interest into various phases of product development,” said Dr. John Ryals, president and CEO of Metabolon.

Milburn received his Ph.D. in structural chemistry at the University of California, Berkeley, and was a Research Fellow at Harvard Medical School for his postdoctoral work.